1,348 research outputs found
Comparison of the effects of metoprolol and carvedilol on symptoms, well.-being, and quality-adjusted life-years: A description of the patient-journey in COMET.
No full textPredischarge echo-Doppler predictors of late cardiac remodeling in the placebo arm of the PRIEAMI echo study
No full textSecondary prevention of coronary disease with ACE inhibition-does blood pressure reduction with perindopril exlain the benefits in EUROPA?
No full textAims We determined whether blood pressure (BP) lowering
by perindopril was related to its benefit in the EUROPA
study.
Methods and results Twelve thousand two hundred eighteen
patients with documented coronary artery disease
received perindopril 8 mg once daily or matching placebo
after a 4-week run-in period in which all patients received
perindopril. Patients were excluded if systolic (S) BP was
>180 or <100 mmHg. Mean age was 60 years (range 26–
89). 27% had a history of hypertension. After 4.2 years of
follow-up, the primary endpoint (cardiovascular death,
nonfatal myocardial infarction, or resuscitated cardiac
arrest) was observed in 603 (9.9%) placebo versus 488
(8.0%) perindopril patients [20% relative risk reduction
(RRR), CI 9–29%, P=0.003]. There was no interaction
between baseline SBP levels (using JNC-7 cutoff values)
and treatment effect. If anything, the greatest RRR of the
primary endpoint (32%) occurred in patients with the
lowest SBP (<120 mmHg) in whom perindopril did not
reduce SBP. Also, RRR during blinded treatment was
comparable, irrespective of whether BP decreased or not or
of the extent of BP reduction during perindopril treatment.
Conclusion The treatment benefit in EUROPA cannot be
fully explained by baseline BP or BP reduction with
perindopril. Other mechanisms including direct anti-atherosclerotic
effects of ACE inhibition may play a role.
Key words Blood pressure . Coronary artery disease .
Secondary prevention . Perindopril .
Anti-atherosclerotic propertie
Comparison of the effects of metoprolol and carvedilol on symptoms, well.-being, and quality-adjusted life-years: A description of the patient-journey in COMET
No full textConsistent survival benefit of carvedilol over metoprolol irrespective of baseline characteristics of heart failure patients – Mode of death evaluation in COMET.
No full textConsistent survival benefit of carvedilol over metoprolol irrespective of baseline characteristics of heart failure patients – Mode of death evaluation in COMET
No full textACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT
No full textACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINEN
Ashburn Anstalt v WJ Arnold & Co. Ltd [1989] Ch 1, Court of Appeal
No full textEssential Cases: Land Law provides a bridge between course textbooks and key case judgments. This case document summarizes the facts and decision in Ashburn Anstalt v WJ Arnold & Co. Ltd [1989] Ch 1, Court of Appeal. The document also includes supporting commentary from author Aruna Nair.</p
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
No full textComparison of the effects of metoprolol and carvedilol on symptoms, well-being and quality-adjusted life-years: a description of the “patient-journey” in COMET.
No full text- …
